Alkermes Plc
ALKS
查看详细走势图
28.520USD
+0.030+0.11%
收盘 12/24, 16:00（美东）报价延迟15分钟
4.71B总市值
13.82市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.11%
5天
+2.55%
1月
-1.62%
6月
-1.31%
今年开始到现在
-0.83%
1年
-3.81%
查看详细走势图
TradingKey Alkermes Plc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Alkermes Plc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名16/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价43.88。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Alkermes Plc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
17
位分析师
买入
评级
43.875
目标均价
+49.18%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Alkermes Plc亮点
亮点风险
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
业绩高增长
公司营业收入稳步增长，连续3年增长40.10%
估值合理
公司最新PE估值13.82，处于3年历史合理位
机构减仓
最新机构持股175.23M股，环比减少0.01%
查克·罗伊斯持仓
明星投资者查克·罗伊斯持仓，最新持仓市值49.77K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.31
Alkermes Plc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Alkermes Plc简介
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
公司代码ALKS
公司Alkermes Plc
CEOPops (Richard F)
网址https://www.alkermes.com/
常见问题
Alkermes Plc(ALKS)的当前股价是多少？
Alkermes Plc(ALKS)的当前股价是 28.520。
Alkermes Plc的股票代码是什么？
Alkermes Plc的股票代码是ALKS。
Alkermes Plc股票的52周最高点是多少？
Alkermes Plc股票的52周最高点是36.450。
Alkermes Plc股票的52周最低点是多少？
Alkermes Plc股票的52周最低点是25.165。
Alkermes Plc的市值是多少？
Alkermes Plc的市值是4.71B。
Alkermes Plc的净利润是多少？
Alkermes Plc的净利润为367.07M。
现在Alkermes Plc(ALKS)的股票是买入、持有还是卖出？
根据分析师评级，Alkermes Plc(ALKS)的总体评级为买入，目标价格为43.875。
Alkermes Plc(ALKS)股票的每股收益（EPS TTM）是多少
Alkermes Plc(ALKS)股票的每股收益（EPS TTM）是2.064。
相关品种
